First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Get Free Report) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 500 shares, an increase of 66.7% from the September 15th total of 300 shares. Based on an average daily volume of 4,300 shares, the short-interest ratio is currently 0.1 days.
Institutional Investors Weigh In On First Trust Nasdaq Pharmaceuticals ETF
A number of large investors have recently modified their holdings of FTXH. Janney Montgomery Scott LLC acquired a new position in shares of First Trust Nasdaq Pharmaceuticals ETF in the 1st quarter valued at $1,030,000. International Assets Investment Management LLC acquired a new stake in First Trust Nasdaq Pharmaceuticals ETF during the 2nd quarter valued at approximately $73,000. Finally, Ameritas Investment Partners Inc. lifted its stake in First Trust Nasdaq Pharmaceuticals ETF by 5.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,200 shares of the company’s stock valued at $314,000 after acquiring an additional 587 shares during the period.
First Trust Nasdaq Pharmaceuticals ETF Stock Up 0.0 %
Shares of NASDAQ FTXH traded up $0.01 during mid-day trading on Monday, reaching $28.67. 1,517 shares of the company were exchanged, compared to its average volume of 5,634. First Trust Nasdaq Pharmaceuticals ETF has a 1 year low of $23.85 and a 1 year high of $29.72. The firm has a 50-day moving average of $28.86 and a 200 day moving average of $27.75. The stock has a market cap of $17.20 million, a price-to-earnings ratio of 15.98 and a beta of 0.70.
First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend
First Trust Nasdaq Pharmaceuticals ETF Company Profile
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.
Further Reading
- Five stocks we like better than First Trust Nasdaq Pharmaceuticals ETF
- Best Stocks Under $10.00
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- What does consumer price index measure?
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.